127 related articles for article (PubMed ID: 31493826)
1. Ichthyosiform Reaction Related to Ponatinib Therapy.
Fernández-González P; Buendía-Castaño D; Saceda-Corralo D; Jaen-Olasolo P
Actas Dermosifiliogr (Engl Ed); 2019 Dec; 110(10):873-875. PubMed ID: 31493826
[No Abstract] [Full Text] [Related]
2. Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities.
Alloo A; Sheu J; Butrynski JE; DeAngelo DJ; George S; Murphy GF; LeBoeuf NR
Br J Dermatol; 2015 Aug; 173(2):574-7. PubMed ID: 25736577
[No Abstract] [Full Text] [Related]
3. Ponatinib-induced widespread ichthyosiform eruption.
Derlino F; Barruscotti S; Zappasodi P; Brazzelli V; Vassallo C
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e519-e521. PubMed ID: 28557248
[No Abstract] [Full Text] [Related]
4. Ichthyosiform eruption and facial erythema secondary to ponatinib therapy.
Munera-Campos M; Carrascosa JM; Quer A; Ferrándiz C
J Dtsch Dermatol Ges; 2020 Jul; 18(7):743-747. PubMed ID: 32589336
[No Abstract] [Full Text] [Related]
5. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis.
Xu H; Busam KJ; Mauro MJ; Markova A
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469781
[TBL] [Abstract][Full Text] [Related]
7. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
[No Abstract] [Full Text] [Related]
8. The accelerated approval of oncologic drugs: lessons from ponatinib.
Prasad V; Mailankody S
JAMA; 2014 Jan 22-29; 311(4):353-4. PubMed ID: 24449310
[No Abstract] [Full Text] [Related]
9. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
10. Ponatinib-induced lamellar ichthyosis-like eruption.
Thakur V; Malhotra P; Lad D; Chatterjee D; Vinay K; Dogra S
Int J Dermatol; 2020 May; 59(5):e156-e157. PubMed ID: 32196645
[No Abstract] [Full Text] [Related]
11. Ponatinib superior to imatinib in Ph
Sidaway P
Nat Rev Clin Oncol; 2024 Jul; 21(7):483. PubMed ID: 38806653
[No Abstract] [Full Text] [Related]
12. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
13. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
[No Abstract] [Full Text] [Related]
14. Lamellar ichthyosis-like eruption associated with ponatinib.
Örenay ÖM; Tamer F; Sarıfakıoğlu E; Yıldırım U
Acta Dermatovenerol Alp Pannonica Adriat; 2016 Sep; 25(3):59-60. PubMed ID: 27695870
[No Abstract] [Full Text] [Related]
15. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary hypertension associated with ponatinib therapy.
Quilot FM; Georges M; Favrolt N; Beltramo G; Foignot C; Grandvuillemin A; Montani D; Bonniaud P; Camus P
Eur Respir J; 2016 Feb; 47(2):676-9. PubMed ID: 26743481
[No Abstract] [Full Text] [Related]
18. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib-associated panniculitis: Case report and review of the literature.
Antwi-Amoabeng D; Ghuman J; Ghuman J; Beutler BD; Ulanja MB; Kuriakose K; Bowman A
Cancer Treat Res Commun; 2021; 27():100357. PubMed ID: 33756173
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
